Condition: Prurigo Nodularis (PN) · Sponsor: UMC Utrecht
With the arrival of dupilumab as the first available targeted therapy for PN, there is an unmet need for real-world data and translational research on the working mechanism of dupilumab on PN, to optimize individualized targeted treatment.
This description comes directly from the study's public registry record.
Marjolein de Bruin-Weller, Professor · 000 · m.s.debruin-weller@umcutrecht.nl
Always discuss trial participation with your own doctor first.
| University Medical Center Utrecht | Utrecht, Utrecht, Netherlands | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07276425